NEW YORK (GenomeWeb) – California-based precision cancer blood-testing company CellMax Life has partnered with Core Diagnostics, a clinical laboratory in India, to introduce two precision cancer risk assessment and screening tests in that country.
Core Diagnostics focuses on next generation diagnostics for disease stratification and therapy selection, with initial test offerings in the areas of cardiology, oncology, reproductive disorders, endocrinology, and infectious diseases.
The CellMax tests now offered by Core will include the CellMax-DNA Genetic Cancer Risk Test — a saliva-based DNA test to determine cancer risk through evaluation of 98 genes across 25 hereditary cancers — and the CellMax-LBx Liquid Biopsy assay — a non-invasive circulating tumor DNA blood test that analyzes 73 genes to improve cancer treatment management, monitor treatment response, and screen for recurrence.
In India, fewer than 30 percent of people diagnosed with cancer survive more than five years after diagnosis, the firms noted in a statement. The goal of the partnership is to empower individuals with personalized and precision cancer risk assessment and screening to enable the earliest possible cancer detection and treatment.
"CellMax Life is bringing early, non-invasive DNA cancer detection via affordable, accessible, accurate cancer saliva and blood tests," CellMax President and CEO Atul Sharan added. "Core Diagnostics is unique in India because of its clear priority toward making next generation diagnostics accessible throughout the country, through its high-quality medical infrastructure and bold innovation."